Palisade Bio Net Income
| PALI Stock | USD 1.73 0.01 0.57% |
As of the 14th of February 2026, Palisade Bio holds the Risk Adjusted Performance of 9.0E-4, coefficient of variation of (10,163), and Variance of 46.13. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Palisade Bio, as well as the relationship between them.
Palisade Bio's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Palisade Bio's valuation are provided below:Palisade Bio does not presently have any trending fundamental ratios for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Is there potential for Biotechnology market expansion? Will Palisade introduce new products? Factors like these will boost the valuation of Palisade Bio. Anticipated expansion of Palisade directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about Palisade Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Palisade Bio is measured differently than its book value, which is the value of Palisade that is recorded on the company's balance sheet. Investors also form their own opinion of Palisade Bio's value that differs from its market value or its book value, called intrinsic value, which is Palisade Bio's true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Palisade Bio's market value can be influenced by many factors that don't directly affect Palisade Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Palisade Bio's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Palisade Bio should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Palisade Bio's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Palisade Bio 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Palisade Bio's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Palisade Bio.
| 11/16/2025 |
| 02/14/2026 |
If you would invest 0.00 in Palisade Bio on November 16, 2025 and sell it all today you would earn a total of 0.00 from holding Palisade Bio or generate 0.0% return on investment in Palisade Bio over 90 days. Palisade Bio is related to or competes with Aspire BioPharma, Curis, Processa Pharmaceuticals, Briacell Therapeutics, Hoth Therapeutics, Citius Pharmaceuticals, and Dare Bioscience. Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing ... More
Palisade Bio Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Palisade Bio's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Palisade Bio upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.02) | |||
| Maximum Drawdown | 31.35 | |||
| Value At Risk | (10.26) | |||
| Potential Upside | 10.53 |
Palisade Bio Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Palisade Bio's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Palisade Bio's standard deviation. In reality, there are many statistical measures that can use Palisade Bio historical prices to predict the future Palisade Bio's volatility.| Risk Adjusted Performance | 9.0E-4 | |||
| Jensen Alpha | (0.05) | |||
| Total Risk Alpha | (0.58) | |||
| Treynor Ratio | 0.16 |
Palisade Bio February 14, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 9.0E-4 | |||
| Market Risk Adjusted Performance | 0.17 | |||
| Mean Deviation | 5.44 | |||
| Coefficient Of Variation | (10,163) | |||
| Standard Deviation | 6.79 | |||
| Variance | 46.13 | |||
| Information Ratio | (0.02) | |||
| Jensen Alpha | (0.05) | |||
| Total Risk Alpha | (0.58) | |||
| Treynor Ratio | 0.16 | |||
| Maximum Drawdown | 31.35 | |||
| Value At Risk | (10.26) | |||
| Potential Upside | 10.53 | |||
| Skewness | 0.1184 | |||
| Kurtosis | (0.36) |
Palisade Bio Backtested Returns
Palisade Bio maintains Sharpe Ratio (i.e., Efficiency) of close to zero, which implies the firm had a close to zero % return per unit of risk over the last 3 months. Palisade Bio exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check Palisade Bio's Coefficient Of Variation of (10,163), variance of 46.13, and Risk Adjusted Performance of 9.0E-4 to confirm the risk estimate we provide. The company holds a Beta of -0.48, which implies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Palisade Bio are expected to decrease at a much lower rate. During the bear market, Palisade Bio is likely to outperform the market. At this point, Palisade Bio has a negative expected return of -0.0657%. Please make sure to check Palisade Bio's potential upside, as well as the relationship between the daily balance of power and market facilitation index , to decide if Palisade Bio performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.28 |
Poor predictability
Palisade Bio has poor predictability. Overlapping area represents the amount of predictability between Palisade Bio time series from 16th of November 2025 to 31st of December 2025 and 31st of December 2025 to 14th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Palisade Bio price movement. The serial correlation of 0.28 indicates that nearly 28.0% of current Palisade Bio price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.28 | |
| Spearman Rank Test | -0.16 | |
| Residual Average | 0.0 | |
| Price Variance | 0.05 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Palisade Bio reported net income of (14.44 Million). This is 104.23% lower than that of the Biotechnology sector and 120.61% lower than that of the Health Care industry. The net income for all United States stocks is 102.53% higher than that of the company.
Palisade Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Palisade Bio's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Palisade Bio could also be used in its relative valuation, which is a method of valuing Palisade Bio by comparing valuation metrics of similar companies.Palisade Bio is currently under evaluation in net income category among its peers.
Palisade Fundamentals
| Return On Equity | -2.29 | ||||
| Return On Asset | -0.88 | ||||
| Current Valuation | 254.6 M | ||||
| Shares Outstanding | 149 M | ||||
| Shares Owned By Insiders | 0.02 % | ||||
| Shares Owned By Institutions | 48.04 % | ||||
| Number Of Shares Shorted | 21.1 M | ||||
| Price To Earning | 0.16 X | ||||
| Price To Book | 80.88 X | ||||
| Price To Sales | 14.03 X | ||||
| EBITDA | (14.42 M) | ||||
| Net Income | (14.44 M) | ||||
| Cash And Equivalents | 5 M | ||||
| Cash Per Share | 0.23 X | ||||
| Total Debt | 169 K | ||||
| Debt To Equity | 0.23 % | ||||
| Current Ratio | 2.59 X | ||||
| Book Value Per Share | 0.35 X | ||||
| Cash Flow From Operations | (12.19 M) | ||||
| Short Ratio | 3.56 X | ||||
| Earnings Per Share | (2.07) X | ||||
| Target Price | 13.4 | ||||
| Beta | 1.61 | ||||
| Market Capitalization | 259.61 M | ||||
| Total Asset | 10.88 M | ||||
| Retained Earnings | (135.94 M) | ||||
| Working Capital | 7.26 M | ||||
| Net Asset | 10.88 M |
About Palisade Bio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Palisade Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Palisade Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Palisade Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out For more detail on how to invest in Palisade Stock please use our How to Invest in Palisade Bio guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is there potential for Biotechnology market expansion? Will Palisade introduce new products? Factors like these will boost the valuation of Palisade Bio. Anticipated expansion of Palisade directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about Palisade Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Palisade Bio is measured differently than its book value, which is the value of Palisade that is recorded on the company's balance sheet. Investors also form their own opinion of Palisade Bio's value that differs from its market value or its book value, called intrinsic value, which is Palisade Bio's true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Palisade Bio's market value can be influenced by many factors that don't directly affect Palisade Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Palisade Bio's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Palisade Bio should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Palisade Bio's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.